Varicella Zoster vaccination in hemodialysis patients: The state of the art
Human Vaccines & Immunotherapeutics, 2023 Varicella Zoster Virus (VZV) infection is a common childhood exanthematous disease, which in adults and immunocompromised people may result in severe neurologic complications.
Laura Gobbi +4 more
doaj +1 more source
Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine [PDF]
Clinical Infectious Diseases, 2019 Abstract The adjuvanted recombinant glycoprotein E herpes zoster (HZ) vaccine is superior to the live attenuated HZ vaccine, with an efficacy >90% against HZ in healthy immunocompetent adults aged ≥50 years after vaccination. In pivotal studies, the efficacy of the new vaccine varied very little with the age of the vaccinee and ...
Myron J, Levin, Adriana, Weinberg
openaire +2 more sources
Research Trends and Hotspots on Herpes Zoster: A 10-Year Bibliometric Analysis (2012–2021)
Frontiers in Medicine, 2022 PurposeHerpes zoster infection, with its considerable burden to individuals and society, remains a challenge around the world. However, to the knowledge of the authors, little bibliometric quantitative or qualitative analysis has been carried out to ...
Jian Zhang +6 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2022 The goal of this research was to describe treatment patterns, health-care resource utilization, and costs for herpes zoster (HZ)-related pain, and to estimate the potential impact of recombinant zoster vaccine (RZV) on avoided HZ cases and HZ-related ...
Jean-Etienne Poirrier +6 more
doaj +1 more source
Rhabdomyolysis after recombinant zoster vaccination: a rare adverse reaction [PDF]
Journal of Community Hospital Internal Medicine Perspectives, 2021 We present a case report describing a potential rare adverse reaction of the recombinant zoster vaccination. This patient is a 60-year-old female who was admitted for severe rhabdomyolysis after receiving the vaccine. The patient's symptoms and CPK improved with aggressive hydration over several days.
Nishan Rajaratnam +4 more
openaire +3 more sources
The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine [PDF]
The Journal of Infectious Diseases, 2020 Abstract Background Efficacy of the live-attenuated herpes zoster (HZ) vaccine (ZVL) wanes substantially over time. We evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) in previous ZVL recipients. Methods
Alemnew F Dagnew +7 more
openaire +2 more sources
, 2023 Background. The risk of herpes zoster reactivation is increased in immunocompromised patients, especially in those with immune-mediated inflammatory diseases (IMIDs) on Janus kinase inhibitor (JAKi) treatment.
Santiago Munoz-Fernández +21 more
core +1 more source
Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications [PDF]
EClinicalMedicineAiri Poder +2 more
exaly +2 more sources
Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients. [PDF]
, 2021 BACKGROUND Immunization of VZV-seronegative solid organ transplant (SOT) patients using the live-attenuated varicella vaccine is generally contraindicated, leaving no widely applicable immunization option. The recombinant subunit herpes zoster vaccine
Kumar, Deepali +14 more
core +1 more source
Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review
Preventive Medicine Reports, 2022 The purpose of this study was to conduct a systematic review to evaluate the cost-effectiveness evidence of herpes zoster vaccines in the U.S. A systematic literature review was undertaken for U.S.
Neil R. Meredith, Edward P. Armstrong
doaj +1 more source